Anaphylaxis: Emergency Diagnosis and Treatment

Anaphylaxis is a life-threatening systemic allergic reaction that demands immediate recognition and treatment to prevent death. This page covers the pathophysiology of anaphylaxis, the clinical criteria used for diagnosis, the most common triggers encountered in emergency settings, and the decision boundaries that guide treatment sequencing. For a broader orientation to the field that governs these protocols, the Emergency Medicine Authority index provides a structured entry point.

Definition and scope

Anaphylaxis is defined by the World Allergy Organization (WAO) as a serious, generalized, or systemic hypersensitivity reaction that is life-threatening because of involvement of the airway, breathing, or circulatory system (WAO Anaphylaxis Guidelines). The National Institute of Allergy and Infectious Diseases (NIAID), in coordination with the Food Allergy and Anaphylaxis Network (FAAN), established clinical criteria specifying that anaphylaxis is highly likely when any one of three diagnostic criteria is met within minutes to hours of exposure to a likely allergen.

The scope of the condition is significant. The estimated lifetime prevalence of anaphylaxis in the United States ranges from 1.6% to 5.1% of the population, according to epidemiological data reviewed by the American Academy of Allergy, Asthma & Immunology (AAAAI). Fatality rates are low but not negligible — the AAAAI cites approximately 1,500 deaths annually in the U.S. attributable to anaphylaxis, with food, medications, and insect stings as the leading causes (AAAAI Anaphylaxis Overview).

Emergency departments operate within a regulatory and clinical framework that treats anaphylaxis as a time-critical emergency. The regulatory context for emergency medicine includes federal mandates under the Emergency Medical Treatment and Labor Act (EMTALA), which requires stabilizing treatment regardless of insurance status.

How it works

Anaphylaxis is mediated primarily through immunoglobulin E (IgE)-dependent mechanisms. On initial allergen exposure, sensitized individuals produce allergen-specific IgE antibodies that bind to high-affinity receptors on mast cells and basophils. On re-exposure, the allergen cross-links these IgE-receptor complexes, triggering rapid degranulation.

Degranulation releases a cascade of preformed and newly synthesized mediators:

  1. Histamine — causes vasodilation, increased vascular permeability, smooth muscle contraction, and pruritus
  2. Tryptase — a serum marker useful in confirming diagnosis; peak levels occur 60–90 minutes post-reaction
  3. Leukotrienes (LTC4, LTD4, LTE4) — contribute to bronchoconstriction and mucus hypersecretion
  4. Prostaglandin D2 — potentiates vasodilation and platelet aggregation inhibition
  5. Platelet-activating factor (PAF) — implicated in severe, biphasic, and fatal reactions

The result is simultaneous multi-system compromise: airway edema (angioedema of the larynx and pharynx), bronchospasm, distributive shock from massive vasodilation, and gastrointestinal dysmotility. Cardiovascular collapse can occur within minutes.

A critical distinction exists between IgE-mediated and non-IgE-mediated (anaphylactoid) reactions. Non-IgE-mediated reactions — such as those caused by radiocontrast media or aspirin — produce an identical clinical picture through direct mast cell activation without prior sensitization. The NIAID/FAAN criteria and the WAO clinical criteria apply equally to both reaction types because treatment is identical regardless of immunological mechanism.

Common scenarios

Three categories of triggers account for the majority of anaphylaxis cases managed in U.S. emergency departments:

Food allergens — Peanuts, tree nuts, shellfish, fish, milk, and wheat represent the most common food triggers. Food-induced anaphylaxis is the leading cause in pediatric populations, as documented in epidemiological reviews published through the Journal of Allergy and Clinical Immunology.

Medications — Beta-lactam antibiotics (penicillins and cephalosporins) and non-steroidal anti-inflammatory drugs (NSAIDs) account for a large proportion of drug-induced anaphylaxis in the ED. Neuromuscular blocking agents are a recognized trigger in perioperative settings. Biologic agents and monoclonal antibodies represent an increasing source of drug hypersensitivity reactions.

Hymenoptera venom — Stings from bees, wasps, yellow jackets, hornets, and fire ants are responsible for approximately 40–100 fatalities per year in the U.S. (AAAAI). Venom anaphylaxis is more commonly fatal in adults than in children, with cardiovascular collapse rather than airway compromise being the dominant mechanism.

Exercise-induced and idiopathic — Exercise-induced anaphylaxis can occur with or without a food co-trigger (food-dependent exercise-induced anaphylaxis, FDEIA). Idiopathic anaphylaxis — where no trigger is identified after thorough evaluation — is diagnosed in approximately 20% of adult cases referred to allergy specialists (AAAAI).

Biphasic anaphylaxis deserves explicit attention: a secondary wave of symptoms can occur 1–72 hours after apparent resolution of the initial reaction without re-exposure to the trigger. The incidence of clinically significant biphasic reactions is estimated at 4–23% across published studies, which directly informs observation period decisions.

Decision boundaries

Treatment sequencing in anaphylaxis follows a hierarchical protocol grounded in published guidelines from the NIAID/FAAN Expert Panel, the WAO, and the American College of Emergency Physicians (ACEP).

Epinephrine is first-line therapy — without exception. The NIAID/FAAN guidelines explicitly state that epinephrine has no absolute contraindications in anaphylaxis. Dose: 0.01 mg/kg of 1:1,000 (1 mg/mL) solution intramuscularly into the anterolateral thigh, maximum single dose 0.5 mg in adults. Delay of epinephrine administration is the primary modifiable risk factor in anaphylaxis fatalities.

Antihistamines (H1 and H2 blockers) and corticosteroids are adjunctive only — they do not reverse airway edema or shock and must never substitute for or delay epinephrine. This boundary is frequently misapplied in clinical practice.

The key decision boundaries are:

  1. Airway patency assessment — Stridor, dysphonia, or drooling indicates impending laryngeal obstruction; early definitive airway management (intubation or surgical airway) is prioritized over other interventions. See airway management in emergency medicine for procedural detail.
  2. Epinephrine non-response — Patients who fail to respond to two intramuscular epinephrine doses require intravenous epinephrine infusion (1–4 mcg/min, titrated), IV fluid resuscitation (1–2 L crystalloid bolus for hypotension), and vasopressor support (norepinephrine or vasopressin for refractory distributive shock).
  3. Observation duration — The WAO recommends a minimum 4–6 hour observation period for mild-to-moderate reactions resolved with a single epinephrine dose; 8–24 hours for severe reactions or those requiring multiple epinephrine doses, given the biphasic risk.
  4. Beta-blocker complication — Patients on beta-blockers may exhibit epinephrine resistance and paradoxical bradycardia; glucagon (1–2 mg IV) is indicated as a bridge agent in this subset.
  5. Discharge criteria — Discharge requires complete symptom resolution, stable vital signs, patient education on self-injectable epinephrine, and a documented follow-up plan with allergy-immunology. Autoinjector prescription at discharge is a quality metric tracked by ACEP and the Joint Commission.

Emergency physicians managing anaphylaxis operate under scope-of-practice frameworks that intersect directly with hospital credentialing and prehospital coordination — areas detailed in scope of practice: emergency medicine and prehospital emergency care and EMS systems.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)